NR 546 Midterm Exam Advanced Psychopharmacology PMHNP | 2026/2027 | Practice Questions with Verified Answers & Detailed Rationales | NGN Grade A | Psychiatric Mental Health Nurse Practitioner | Downloadable PDF

INSTANT PDF DOWNLOAD — This is the comprehensive Midterm Exam preparation guide for NR 546 - Advanced Psychopharmacology (2026/2027) for Psychiatric Mental Health Nurse Practitioner (PMHNP) students, featuring practice questions with verified answers and detailed rationales. Designed for PMHNP students preparing for advanced psychopharmacology examinations, this resource consolidates the essential pharmacologic concepts required to master the NR 546 Midterm Exam and excel in psychiatric medication management. The guide is meticulously aligned with ANCC PMHNP-BC® certification blueprints, DSM-5-TR diagnostic criteria, and current evidence-based psychopharmacology standards. This verified resource provides comprehensive coverage of key NR 546 Advanced Psychopharmacology exam topics, including: Neurotransmitter Systems (serotonin (5-HT)—synthesis from tryptophan via tryptophan hydroxylase (TPH), metabolism by MAO-A to 5-HIAA, receptors (5-HT1A (postsynaptic (anxiolysis, antidepressant, BDNF upregulation), presynaptic (autoreceptor, inhibits 5-HT release, somatodendritic), partial agonists (buspirone, vilazodone, gepirone, tandospirone), full agonists (flesinoxan, EMD 68843, not available in US), antagonists (WAY-100635 (research), pindolol (weak, used as augmentation for SSRIs to block 5-HT1A autoreceptors, accelerate antidepressant response, controversial)), 5-HT1B (presynaptic autoreceptor (inhibits 5-HT release), also on blood vessels (vasoconstriction), triptans (sumatriptan, rizatriptan, eletriptan, zolmitriptan, almotriptan, naratriptan, frovatriptan) for acute migraine, agonists at 5-HT1B/1D/1F, contraindicated with MAOIs, ergotamines, within 24 hours, risk serotonin syndrome, coronary vasospasm (contraindicated in CAD, Prinzmetal's angina, uncontrolled hypertension, stroke, peripheral vascular disease)), 5-HT2A (postsynaptic, excitatory, psychosis (hallucinations, delusions, thought disorder), antagonism by atypical antipsychotics (clozapine, olanzapine, risperidone, quetiapine, ziprasidone, aripiprazole (partial agonist), asenapine, paliperidone, iloperidone, lurasidone, brexpiprazole, cariprazine) improves positive symptoms, reduces EPS risk, improves cognition, psychedelic hallucinogens (LSD, psilocybin (magic mushrooms), mescaline (peyote), DMT (ayahuasca), DOM, DOI, 2C-B, 2C-I, 25I-NBOMe) act as 5-HT2A agonists (also 5-HT1A, 5-HT2C, 5-HT6, dopamine D2, adrenergic alpha-2, sigma-1, trace amine-associated receptor (TAAR1)), induce mystical-type experiences, ego dissolution, altered perception of time, space, self, visual hallucinations, synesthesia, used in research for depression (psilocybin), PTSD (MDMA (ecstasy) is primarily serotonin releaser (SERT substrate, reverses transporter, increases synaptic 5-HT, also releases NE, DA, oxytocin, prolactin, cortisol, vasopressin, ACTH, neuroprotective? neurotoxic at high doses, repeated use, serotonergic axon degeneration, cognitive deficits, memory impairment, depression, anxiety, psychosis, dependence, addiction, cardiotoxicity (QT prolongation, valvular heart disease (5-HT2B agonist), pulmonary hypertension, MI, stroke, hyperthermia, hyponatremia, seizures, serotonin syndrome, death), MDMA-assisted psychotherapy for PTSD (phase 3 clinical trials, FDA breakthrough therapy designation, expected approval 2024?), limited to controlled setting, with psychotherapy, not for recreational use)), 5-HT2C (postsynaptic, regulates appetite (activation causes satiety, weight loss), antagonists cause weight gain (clozapine, olanzapine, quetiapine, risperidone (weak), asenapine, zotepine, lurasidone (minimal), aripiprazole (neutral), cariprazine (neutral), brexpiprazole (neutral)), also regulates mood, anxiety, impulsivity, aggression, locomotion, seizures, neuroendocrine function (HPA axis), agonists (lorcaserin (Belviq, withdrawn 2020 due to increased cancer risk)), 5-HT3 (ion channel, in chemoreceptor trigger zone (area postrema), vagus nerve, GI tract, causes nausea/vomiting, antagonists (ondansetron (Zofran), granisetron, dolasetron, palonosetron, alosetron (Lotronex for IBS-D, withdrawn, restricted use)), for chemotherapy-induced nausea/vomiting (CINV), postoperative nausea/vomiting (PONV), radiation-induced nausea/vomiting, gastroenteritis, pregnancy (hyperemesis gravidarum), off-label for anxiety, IBS, schizophrenia (clozapine, olanzapine, quetiapine have 5-HT3 antagonism, contributes to antiemetic effect, anxiolytic effect), side effects (constipation, headache, dizziness, fatigue, QT prolongation (ondansetron 16 mg dose, avoid high doses, hypokalemia, hypomagnesemia, bradycardia, other QT-prolonging drugs), serotonin syndrome (if combined with serotonergic drugs (SSRIs, SNRIs, MAOIs, buspirone, tramadol, meperidine, fentanyl, methadone, dextromethorphan, linezolid, methylene blue, St. John's wort, triptans, ecstasy, LSD, psilocybin, cocaine, amphetamines), avoid combining multiple serotonergic drugs, educate patients about signs (agitation, confusion, diaphoresis, hyperthermia, tachycardia, hypertension, hyperreflexia, clonus, tremor, rigidity, mydriasis, diarrhea, nausea, vomiting, seizures, coma, death), treatment (stop serotonergic drugs, supportive care, benzodiazepines (lorazepam, diazepam, midazolam) for agitation, seizures, muscle rigidity, cyproheptadine (5-HT2A antagonist) 12 mg PO then 8 mg q6h, atypical antipsychotics (olanzapine, quetiapine) may worsen serotonin syndrome? avoid, use benzodiazepines, ICU admission for severe (hyperthermia 40°C, seizures, status epilepticus, respiratory failure, renal failure, DIC, rhabdomyolysis, metabolic acidosis, hyperkalemia, death), dantrolene for rigidity? not recommended, paralysis and intubation for severe rigidity, hyperthermia, cooling blankets, IV fluids, vasopressors for hypotension, sodium bicarbonate for metabolic acidosis, dialysis for renal failure)), dopamine (DA)—synthesis from tyrosine via tyrosine hydroxylase (TH) (rate-limiting), DOPA